Katayose Yu, Nakagawa Kei, Onogawa Tohru, Yoshida Hiroshi, Motoi Fuyuhiko, Naitoh Takeshi, Rikiyama Toshiki, Egawa Shinichi, Unno Michiaki
Integrated Surgery and Oncology, Tohoku University Graduate School of Medicine.
Gan To Kagaku Ryoho. 2011 Dec;38(13):2651-3.
As chemotherapy advances, patients who had liver metastases often come to receive liver resection after their chemotherapy, including oxaliplatin-based chemotherapy. We experienced a case of an acute hypersensitivity reaction to reintroduced-oxaliplatin at the second course of oxaliplatin-based adjuvant chemotherapy, after neoadjuvant chemotherapy for liver metastases originating from colon cancer. There is a report that hypersensitivity reactions are frequent in the second course of the reintroduced-oxaliplatin-based regimen. It is thought that the prevention is necessary at the second course even if there is no significant symptom at the first course. Similar cases will increase as neoadjuvant therapies spread in the future; therefore, prescriptions for preventing hypersensitivity are necessary when administering reintroduced-oxaliplatin base chemotherapy.
随着化疗技术的进步，发生肝转移的患者在接受包括以奥沙利铂为基础的化疗在内的化疗后，常常会接受肝切除术。我们遇到了这样一个病例，一名结肠癌肝转移患者在新辅助化疗后，接受以奥沙利铂为基础的辅助化疗的第二个疗程时，对重新引入的奥沙利铂发生了急性过敏反应。有报告称，在重新引入奥沙利铂的治疗方案的第二个疗程中，过敏反应很常见。即使在第一个疗程没有明显症状，在第二个疗程也有必要进行预防。随着新辅助治疗在未来的推广，类似病例将会增加；因此，在给予重新引入奥沙利铂的基础化疗时，有必要开具预防过敏的处方。
